MetLife (MET)
$74.93
0.15 (0.20%)
MET Stock Quote Delayed 30 Minutes
5 Insurance Stocks to Sell Now
This week, the ratings of five Insurance stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
170.84B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
804,309
Day's Range
$74.34 - $75.33
52-Week Range
$57.91 - $76.90
Dividend & Yield
$2.08 (2.78%)
MET Stock Predictions, Articles, and MetLife News
$500 Million MetLife ‘Death Master’ Settlement
State regulators and MetLife agree to a $500 million settlement over unclaimed life insurance benefits.
Don’t Lose Any Sleep Over Regional Banks’ Stress Tests
Zions and Regions both passed their stress tests, though other analysts have raised their eyebrows. Investors shouldn't sweat the debate -- or the stocks.
15% Return on Solar Investments Attracts Buffett, KKR and Google
U.S. solar developers are luring cash at record rates from investors like Warren Buffett’s Berkshire Hathaway (NYSE:BRK.B) and Google (NASDAQ:GOOG).
Pony Up for American Express
Stress test winner American Express has it all: Solid financial footing, growing revenues and profits, a newly raised dividend -- and an alluring valuation.
Stocks Take a Breather — Wednesday’s IP Market Recap
Investors mostly rested Wednesday -- except for those who hammered PR-challenged Goldman Sachs (GS).
For Now, Stay Away From MetLife
As long as MetLife's Fed oversight status is up in the air, investors should take a pass.
Is It Time to Dump These 4 Health Care ETFs?
These four funds' holdings stand to lose big on health care reform, regardless of the Supreme Court ruling. Investors should assess the damage from the outside.
The Right Way to Buy Rising Stocks
Don't let the fear of being late to the party keep you on the sidelines. Here's a win-win strategy for buying stocks that are on the rise.
